Combining TTFields with gemcitabine and nab-paclitaxel can improve OS in patients with locally advanced pancreatic adenocarcinoma, results of the PANOVA-3 trial suggest.

Vincent Picozzi, MD, discusses findings from the phase 3 trial PANOVA-3 of TTFields with gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer.

Early diagnosis and treatment of pancreatic cancer offer the best odds of beating the disease. Unfortunately, there is still no screening test, such as a blood test, that can reliably detect ...

Pancreatic ductal adenocarcinoma (PDAC) is associated with several genetic syndromes. However, the molecular mechanism underlying PDAC progression is still unknown. In this study, we showed that ...

Other, less common types of pancreatic cancer may differ. For example, squamous adenocarcinoma of the pancreas is associated with very poor outcomes, and neuroendocrine tumors tend to have a better ...

Medical news, education and information for physicians and health care professionals, presented by specialty and topic. From Healio and the Wyanoke Group.